1,844,049 Shares in AnaptysBio, Inc. $ANAB Bought by BlackRock Inc.

Key Points

• BlackRock acquired 1,844,049 AnaptysBio shares during the second quarter, worth approximately $124.5 million and representing a 6.23% ownership stake.
• AnaptysBio shares opened at $56.28, with a 52-week range of $11.40 to $72.36 and a market capitalization of about $1.67 billion.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $80, despite some recent downgrades to “Hold” and one “Sell” rating.

BlackRock Inc. bought a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,844,049 shares of the biotechnology company's stock, valued at approximately $124,473,000. BlackRock Inc. owned 6.23% of AnaptysBio at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Persistent Asset Partners Ltd acquired a new stake in shares of AnaptysBio in the second quarter worth $39,000. Smartleaf Asset Management LLC boosted its stake in shares of AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 821 shares during the last quarter. Larson Financial Group LLC raised its holdings in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 473 shares during the last quarter. Tower Research Capital LLC TRC raised its position in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. lifted its position in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock valued at $52,000 after buying an additional 2,326 shares during the last quarter.

AnaptysBio Stock Performance

AnaptysBio stock opened at $56.28 on Friday. The stock has a 50-day simple moving average of $58.55 and a 200 day simple moving average of $59.06. AnaptysBio, Inc. has a 52 week low of $11.40 and a 52 week high of $72.36. The stock has a market capitalization of $1.67 billion, a P/E ratio of -52.11 and a beta of 0.72.

Analysts Set New Price Targets

Several equities analysts recently commented on ANAB shares. Wall Street Zen lowered AnaptysBio from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 16th. Weiss Ratings restated a "sell (e+)" rating on shares of AnaptysBio in a report on Friday, August 7th. Leerink Partners set a $90.00 price objective on AnaptysBio in a research note on Friday, May 15th. Scotiabank cut AnaptysBio to a "hold" rating and set a $70.00 price objective for the company. in a report on Tuesday. Finally, Zacks Research lowered shares of AnaptysBio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, AnaptysBio currently has an average rating of "Moderate Buy" and an average price target of $80.00.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source